Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,041
datasets available to search
ShareScore release 0.7.1
Dataset results
1,041 results for “cardiovascular diseases”
Shared genetic factors between stress-related disorders and cardiovascular disease
<p>The ultimate goal of this study is to advance our understanding of the biological mechanisms of stress-related disorders and CVD, through demonstrating pleiotropic genes and pathways underlying their comorbidity that are potentially testable as targets of future interventions in experimental investigations.</p>
Assessment of skin autofluorescence and its association with glycated hemoglobin, cardiovascular risk markers and concomitant chronic diseases in children with type 1 diabetes
<p>This is the dataset for the publication "Assessment of skin autofluorescence and its association with glycated hemoglobin, cardiovascular risk markers and concomitant chronic diseases in children with type 1 diabetes".</p>
E-Cigarette Effects on Markers of Cardiovascular and Pulmonary Disease
ClinicalTrials.gov study NCT03863509. IPD Sharing: YES. Countries: 1. Publications: 1.
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER St
ClinicalTrials.gov study NCT04216589. IPD Sharing: YES. Countries: 2. Publications: 2.
Reducing Cardiovascular Disease Risk in Perimenopausal Latinas
ClinicalTrials.gov study NCT04313751. IPD Sharing: YES. Countries: 1. Publications: 3.
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
ClinicalTrials.gov study NCT03060577. IPD Sharing: YES. Countries: 5. Publications: 2.
A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Rec
ClinicalTrials.gov study NCT04929249. IPD Sharing: YES. Countries: 1. Publications: 1.
A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention
ClinicalTrials.gov study NCT04545489. IPD Sharing: YES. Countries: 1. Publications: 2.
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
ClinicalTrials.gov study NCT01327846. IPD Sharing: YES. Countries: 40. Publications: 18.
Risk factors for cardiovascular disease (CVD) in adults with type 1 diabetes: findings from prospective real-life T1D exchange registry
<p>Context</p> <p>Cardiovascular disease (CVD) is a major cause of mortality in adults with type 1 diabetes.</p> <p>Objective</p> <p>We prospectively evaluated CVD risk factors in a large, contemporary cohort of adults with type 1 diabetes living in the United States.</p> <p>Design</p> <p>Observational study of CVD and CVD risk factors over a median of 5.3 years.</p> <p>Setting</p> <p>The T1D Exchange clinic network.</p> <p>Patients</p> <p>Adults (age ≥18 years) with type 1 diabetes and without known CVD diagnosed before or at enrollment.</p> <p>Main Outcome Measure</p> <p>Associations between CVD risk factors and incident CVD were assessed by multivariable logistic regression.</p> <p>Results</p> <p>The study included 8,727 participants (53% female, 88% non-Hispanic white, median age 33 years [IQR=21, 48], type 1 diabetes duration 16 years [IQR=9, 26]). At enrollment, median HbA1c was 7.6% (66 mmol/mol) [IQR=6.9 (52), 8.6 (70)], 33% used a statin, and 37% used blood pressure medication. Over a mean follow-up of 4.6 years, 325 (3.7%) participants developed incident CVD. Ischemic heart disease was the most common CVD event. Increasing age, BMI, HbA1c, presence of hypertension and dyslipidemia, increasing duration of diabetes, and diabetic nephropathy were associated with increased risk for CVD. There were no significant gender differences in CVD risk.</p> <p>Conclusion</p> <p>HbA1c, hypertension, dyslipidemia and diabetic nephropathy are important risk factors for CVD in adults with type 1 diabetes. A longer follow-up is likely required to assess the impact of other traditional CVD risk factors on incident CVD in the current era.</p>
In silico database of ~500 000 virtual patients with diverse cardiovascular disease
<p>The presented dataset contains a large virtual cohort of more than 50'000 heart failure patients characterized by realistic traces of volumes, pressures, flows, and regional mechanics. We used the well-established CircAdapt model <a href="https://www.circadapt.org/">(https://www.circadapt.org/</a> , <a href="http://framework.circadapt.org/">http://framework.circadapt.org/</a>) of the human heart and circulation to simulate a large cohort of virtual patients, covering a wide range of HF-related disease heterogeneity and severity. <br>In the construction of virtual patients, generating a variety of parameter sets for the initial population is essential and can be accomplished using various sampling techniques. In our investigation, we utilized the Sobol-low discrepancy sequence to ensure uniformity across the high-dimensional parameter space. For a more detailed explanation please refer to the document <em>"MARCIUS_deliverable_D1.5_VirtualDatabase.pdf"</em></p> <p><strong>Acknowledgments:</strong> This work was supported by the European Union's Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie grant agreement No. 86074, <strong>"MARCIUS - MARie Curie Intelligent UltraSound"(<a href="https://www.marcius-project.com/">https://www.marcius-project.com/</a>)</strong>. MARCIUS rationale was to develop a comprehensive in silico simulation platform comprising both the generation of virtual patients (<em>presented dataset</em>) and their associated realistic image data. Such approach would make it possible to learn the most relevant patterns within a wide representative set of patients to lead the training of ML-based image processing algorithms in order to analyze real-world clinical data.</p> <p> </p>
Data set related to the article: "The Role of BPIFB4 in Immune System and Cardiovascular Disease: The Lesson from Centenarians."
<p>Abstract:</p> <p>Recent discoveries have shed light on the participation of the immune system in the physio pathology of the car- diovascular system underpinning the importance of keeping the balance of the first to preserve the latter. Aging, along with other risk factors, can challenge such balance triggering the onset of cardiovascular diseases.</p> <p>Among several mediators ensuring the proper cross-talk between the two systems, bactericidal/permeability- increasing fold-containing family B member 4 (BPIFB4) has been shown to have a pivotal role, also by sustaining important signals such as eNOS and PKC-alpha.</p> <p>In addition, the Longevity-associated variant (LAV), which is an haplotype allele in BPIFB4 characterized by 4 missense polymorphisms, enriched in homozygosity in Long Living Individuals (LLIs), has been shown to be efficient, if admin- istered systemically through gene therapy, in improving many aspects of cardiovascular diseases (CVDs). This occurs mainly through a fine immune system remodeling across: 1) a M2 macrophage polarizing effect, 2) a favorable redistri- bution of the circulating monocyte cell subsets and 3) the reduction of T-cell activation. Furthermore, LAV-BPIFB4 treat- ment induced a desirable recovery of the inflammatory balance by mitigating the pro-inflammatory factor levels and enhancing the anti-inflammatory boost through a mechanism that is partially dependent on SDF-1/CXCR4 axis.</p> <p>Importantly, the remarkable effects of LAV-BPIFB4 treatment, which translates in increased BPIFB4 circulating levels, mirror what occurs in long-living individuals (LLIs) in whom the high circulating levels of BPIFB4 are protective from age-related and CVDs and emphasize the reason why LLIs are considered a model of successful aging. Here, we review the mechanisms by which LAV-BPIFB4 exerts its immunomodulatory activity in improving the cardiovascular-immune system dialogue that might strengthen its role as a key mediator in CVDs.</p>
Associations of serum uric acid with cardiovascular disease risk factors: a retrospective cohort study in Southeastern China
<p class="MsoNormal"><span>Objective: To evaluate the associations between serum uric acid (SUA) levels and cardiovascular disease (CVDs) risk factors, focusing on potential sex-specific differences.</span></p> <p class="MsoNormal"><span>Design: A retrospective cohort study.</span></p> <p class="MsoNormal"><span>Setting: A large community-based survey was conducted every two years from 2010 to 2018 in Hangzhou, Zhejiang Province, Southeastern China.</span></p> <p class="MsoNormal"><span>Participants: 6119 participants aged 40 years and above who underwent at least three times of physical examinations were enrolled. </span></p> <p class="MsoNormal"><span>Methods: Participants were categorized into four groups (Q1-Q4) based on baseline SUA quartiles within the normal range, with hyperuricemia (HUA) as the fifth group. The Q1 was the reference. By stratifying participants by gender, the relationships between SUA levels and systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), and total cholesterol (TC) were investigated using linear regression models in the generalized estimating equation (GEE). Additionally, the associations of elevated SUA levels and HUA with hypertension, hyperglycemia, and dyslipidemia were correspondingly examined using multivariate logistic regression models.</span></p> <p class="MsoNormal"><span>Results: After adjusting for confounding variables, we found positive associations between SUA levels and SBP, DBP, FBG, and TC in women, and with TC in men (P < 0.01). Likewise, Elevated SUA quartiles and HUA were linked to increased dyslipidemia risk in both sexes, and increased hyperglycemia risk only in women, with HRs (95%CI) of 1.64 (1.05-2.55) and 2.37 (1.47-3.81) in the Q4 and HUA group, respectively. Women with HUA had higher hypertension risk (HR=1.45, 95% CI 1.21-1.73), while no such association was observed in men. Stratified analyses revealed significant associations between elevated SUA levels and CVDs risk factors in postmenopausal and non-obese women.</span></p> <p class="MsoNormal"><span>Conclusions: Elevated SUA levels increase the risk of dyslipidemia in both sexes. SUA levels within normal-range and HUA are positively associated with hyperglycemia and hypertension in postmenopausal women, but not in men.</span></p>
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
ClinicalTrials.gov study NCT03385239. IPD Sharing: NO. Countries: 2. Publications: 1.
Subclinical Cardiovascular Disease in Psoriatic Disease
ClinicalTrials.gov study NCT03228017. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease
ClinicalTrials.gov study NCT00603590. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
ClinicalTrials.gov study NCT06930885. IPD Sharing: YES. Countries: 1. Publications: 4.
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
ClinicalTrials.gov study NCT00501059. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
ClinicalTrials.gov study NCT01776424. IPD Sharing: NO. Countries: 33. Publications: 66.
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
ClinicalTrials.gov study NCT03643705. IPD Sharing: YES. Countries: 1. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.